在21个美国儿科糖尿病中心中比较糖尿病技术使用情况
Priya Prahalad1, Holly Hardison2, Ori Odugbesan2
1Stanford Children's Health, Lucile Packard Children's Hospital, Stanford, CA.
概括
糖尿病技术的使用,包括持续的葡萄糖监测和胰岛素,在大多数儿科中心都增加了. 然而,在中心之间观察到吸收的显著差异,突出了1型糖尿病管理广泛采用的潜在障碍.
科学领域:
- 内分泌学和新陈代谢学
- 儿童糖尿病管理管理
- 医疗保健服务研究 医疗服务研究
背景情况:
- 美国糖尿病协会建议糖尿病技术 (CGM,胰岛素) 用于1型糖尿病 (T1D) 的管理.
- 包括当地中心实践在内的障碍阻碍了这些基本技术的采用.
- 了解技术采用趋势对于提高T1D护理质量至关重要.
研究的目的:
- 评估2021年至2022年糖尿病技术利用的整体变化.
- 检查儿童糖尿病中心技术采用的中心对中心的变化.
- 在T1D交换质量改进协作中确定对技术采用的潜在影响.
主要方法:
- 糖尿病技术的分析使用来自21个儿科中心的数据.
- 在T1D交换质量改善协作框架内收集的数据.
- 在2021年至2022年期间对技术采用趋势的比较分析.
主要成果:
- 在大多数参与中心中,观察到糖尿病技术使用的普遍增加.
- 在21个中心中发现了技术采用率的显著差异.
- 这些发现表明,在技术获取和使用方面,既有进展,也有持续的差异.
结论:
- 糖尿病技术在儿科1型糖尿病护理中的使用正在增加,与临床建议保持一致.
- 中心之间存在很大的差异表明,当地因素对技术采用有重大影响.
- 需要进一步的研究来解决障碍,并促进对糖尿病技术的公平获取.
相关概念视频
Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Symptoms, Diagnosis, and Complications
546
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
546
Insulin: Dosing Regimen and Adverse Effects
175
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
175
Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263


